NCT06119529

A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis

A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Single-Ascending Dose Study of LY3872386 in Healthy Participants, a Multiple-Ascending Dose Study of LY3872386 in Patients With Atopic Dermatitis, and an Open-Label Multiple-Dose Evaluation of the Safety and Tolerability of Prednisone in Healthy Participants.

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants. Blood tests will be performed to investigate how the body processes the LY3872386 following single and multiple dosing in healthy participants and participants with atopic dermatitis. Blood tests will also be performed to investigate how the body processes the prednisone in healthy participants. The study is conducted in three parts (part A, B and C). The study will last up to approximately 85, 183 and 44 days for parts A, B, and C, respectively.

Conditions

• Healthy
• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	LY3872386	Administered IV.
DRUG	Prednisone	Administered orally.
DRUG	Placebo	Administered IV.

Timeline

• Start date: 2023-11-01
• Primary completion: 2024-04-08
• Completion: 2024-04-08
• First posted: 2023-11-07
• Last updated: 2025-10-03
• Results posted: 2025-10-03

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study